Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Mibefradil Potently Blocks ATP-Activated K+ Channels in Adrenal Cells

Juan Carlos Gomora, Judith A. Enyeart and John J. Enyeart
Molecular Pharmacology December 1999, 56 (6) 1192-1197; DOI: https://doi.org/10.1124/mol.56.6.1192
Juan Carlos Gomora
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith A. Enyeart
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John J. Enyeart
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Mibefradil is a novel Ca2+ channel antagonist that preferentially blocks T-type Ca2+ channels in many cells. Using whole-cell and single-channel patch-clamp recording, we found that mibefradil also potently blocked an ATP-activated K+channel (IAC) expressed by adrenal zona fasciculata cells. IAC channels were inhibited by mibefradil with an IC50 value of 0.50 μM, a concentration 2-fold lower than that required to inhibit T-type Ca2+ channels under similar conditions in the same cells. The inhibition of IAC by mibefradil was independent of the membrane potential. Mibefradil also reversibly blocked, with similar potency, unitary IACcurrents recorded in outside-out membrane patches. An analysis of dwell time histograms indicated the presence of two closed and one open state. Mibefradil (1 μM) increased the duration of the two closed time constants (τc1 and τc2) from 2.30 ± 0.18 and 27.9 ± 4.7 ms to 4.32 ± 0.61 and 62.5 ± 13.8 ms, respectively, but did not alter the open time constant (τo). Mibefradil also failed to reduce the size of the unitary IAC current. A voltage-gated A-type K+current was also inhibited by mibefradil at concentrations approximately 10-fold higher than those required to block IAC (IC50 = 4.65 μM). These results identify mibefradil as a potent inhibitor of ATP-activated K+ channels in adrenal zona fasciculata cells. It appears to function by stabilizing closed states of these channels. In contrast to its selective block of T-type Ca2+ channels, mibefradil may be a potent but less-selective K+ channel blocker. In this regard, the block of K+ channels may produce some of the toxicity associated with mibefradil in cardiovascular pharmacology.

Footnotes

    • Received July 16, 1999.
    • Accepted September 9, 1999.
  • Send reprint requests to: Dr. John J. Enyeart, Department of Pharmacology, The Ohio State University, College of Medicine, 5188 Graves Hall, 333 W. 10th Ave., Columbus, OH 43210-1239. E-mail:enyeart.1{at}osu.edu

  • ↵1 Current address: Loyola University, Stritch School of Medicine, Department of Physiology, Chicago, IL 60153.

  • J.J.E. was supported by National Institute of Diabetes and Digestive and Kidney Grant DK47875.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 56 (6)
Molecular Pharmacology
Vol. 56, Issue 6
1 Dec 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mibefradil Potently Blocks ATP-Activated K+ Channels in Adrenal Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Mibefradil Potently Blocks ATP-Activated K+ Channels in Adrenal Cells

Juan Carlos Gomora, Judith A. Enyeart and John J. Enyeart
Molecular Pharmacology December 1, 1999, 56 (6) 1192-1197; DOI: https://doi.org/10.1124/mol.56.6.1192

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Mibefradil Potently Blocks ATP-Activated K+ Channels in Adrenal Cells

Juan Carlos Gomora, Judith A. Enyeart and John J. Enyeart
Molecular Pharmacology December 1, 1999, 56 (6) 1192-1197; DOI: https://doi.org/10.1124/mol.56.6.1192
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics